Physician profile
Richard I Wright
NPI 1770573552
$9,897.74
in general payments reported to CMS, 2019-2025
55 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $730 · 2021: $1,421 · 2022: $1,454 · 2023: $1,909 · 2024: $1,555 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,513 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,513.18 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,438.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,122.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $763.37 | 2021-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $653.87 | 2021-2025 | Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $589.50 | 2021-2025 | |
| Lilly USA, LLC | $581.04 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $385.88 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $348.94 | 2022-2025 | Hetlioz, Fanapt |
| Pfizer INC. | $348.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $332.21 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $240.38 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.81 | 2020-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $185.41 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.66 | 2025 | Caplyta |
| Abbott Laboratories | $161.07 | 2021-2025 | Freestyle Libre 3 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.